Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry is at its peak, with spaces like weight loss/obesity, inflammation and Alzheimer’s disease attracting investor interest in 2024.Novel diabetes and obesity drugs of Eli Lilly (LLY) and Novo Nordisk have taken the pharma sector by storm with both Eli Lilly’s tirzepatide drugs (Mounjaro and Zepbound) and No ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. The pharmaceutical giant is spending $1 billion to expand an existing site in Limerick, Ireland, to increase the production of certain active ingredients in drugs, including those used ...

There's a little appreciated reason to own Eli Lilly stock, and it has nothing to do with its medicines.Eli Lilly (LLY -0.77%) might just be the hottest pharmaceutical company on the planet right now. The company is the developer of a number of blockbuster drugs including Verzenio, Trulicity, and Taltz.Of course, I'd be remiss to not include the company's latest hits in weight loss. Lilly's diabetes and obesity care medications, Mounjaro and Zepbound, are currently fueling a new wave of growth for the pharm ...

Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.Stock splits can get the market excited, even though nothing changes for the business fundamentally, including its future prospects. So what's the reason behind a rally following a stock split? Once a company's share price goes above a certain psychological threshold, the average investor begins to perceive the stock as "expensive" and worries about being unable to buy enough (or even whole) shares of that c ...

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsit ...

Core Insights - Eli Lilly has been a significant performer for investors, with total returns of 100,203% since 1972, indicating strong historical performance and potential for future growth [2][3] Group 1: GLP-1 Market Potential - The GLP-1 market, driven by weight loss treatments, is still in its early stages, with Eli Lilly positioned to benefit from this growth through its drugs Mounjaro and Zepbound [3][5] - The global total addressable market (TAM) for GLP-1 treatments was valued at $36.8 billion in 2023, with a forecasted compound annual growth rate (CAGR) of 21.6% from 2024 to 2030, potentially exceeding $100 billion by 2030 [4] - Lilly is exploring new indications for its GLP-1 drugs, which could expand their use beyond diabetes and weight management, indicating further growth potential [5] Group 2: Alzheimer's Drug Opportunity - Eli Lilly's Alzheimer's drug, donanemab, received FDA approval, with the current TAM for Alzheimer's therapeutics at $6.5 billion and a forecasted CAGR of 19% from 2024 to 2033, potentially reaching $31 billion [6] - The limited competition in the Alzheimer's treatment space, combined with the strong demand for GLP-1 drugs, positions Lilly favorably for future growth [6] Group 3: AI in Healthcare - Eli Lilly is collaborating with OpenAI to leverage generative AI for developing antimicrobial medications, addressing the significant health concern of antimicrobial resistance (AMR) [7][8] - The World Bank estimates that healthcare costs related to AMR could reach $1 trillion by 2050, highlighting the long-term importance of addressing this issue [8]

This drugmaker should have a basketful of growth drivers over the next decade.Eli Lilly (LLY -1.10%) stands atop the biopharmaceutical world. It's the biggest drugmaker by far based on market cap. Lilly's share price has skyrocketed nearly 700% over the last five years and is up close to 55% in 2024.Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for treating type 2 diabetes and obesity, respectively. But Mounjaro and Zepbound aren' ...

Merck & Co., Inc. NYSE: MRK is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO, with a market capitalization of $294 billion.The company’s forward price-to-earnings (P/E) ratio sits at 13x. Compared to a peer group of the world's 10 largest pharma companies, this is well below the average of 20x. According to FactSet Earnings Insight, the healthcare sector has experienced the fourth-largest earnings growth in the p ...

Eli Lilly (LLY) announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults with type II diabetes (T2D).LLY’s Weekly Insulin Shot Matches Daily InsulinThe QWINT-1 study compared efsitora to daily injections of Sanofi’s (SNY) Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s (N ...

When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower.As you can see on the chart, this is what just happened with shares of Eli Lilly and Co LLY. This is why our team of trading experts have made it our Stock of the Day.When a stock is moving higher, it is out of equilibrium. There is more demand (buy orders) than there is supply (sell orders). As a result, if they want to acquire shares, ...